Psoriasis - 10 Year Clinical Experience Confirms Raptiva’s Long-Term Safety Profile
Safety data from 10 years of clinical development and postmarketing experience in patients treated with Raptiva® (efalizumab), presented at the European Academy of Dermatology and Venereology (EADV) congress, have confirmed the favourable safety profile of Raptiva® in long-term treatment of patients with moderate to severe chronic plaque psoriasis. Psoriasis is a common, chronic and incurable condition that affects 5.7 million people in Europe.
This post is an original post by ScienceDaily: Skin Care News
Posted: May 23rd, 2008 under skin health.
Comments: none
